Please login to the form below

Not currently logged in
Email:
Password:

Paolo Paoletti named as executive chairman of Kesios

Paoletti was formerly president of GSK Oncology

kesios paolo paolettiImperial Innovations Group has appointed Dr Paolo Paoletti as executive chairman of portfolio company Kesios Therapeutics.

Paoletti was formerly the first appointed president of GSK Oncology, where he was responsible for the overall oncology business within the firm and oversaw activities from early drug discovery through to clinical development, launch and life cycle management.

Commenting on his appointment, Paoletti said: “I'm extremely pleased to take this role to accelerate the clinical development of this new molecule and, hopefully, to translate the very innovative and interesting pre-clinical science in an impactful medicine for patients affected by multiple myeloma and other forms of cancer.”

Paoletti is additionally a non-executive director of PsiOxus Therapeutics, Innovation's sixth largest portfolio company, which is developing innovative immune-oncology treatments for cancer.

Maina Bhaman, director of healthcare ventures at Imperial Innovations, said: “We are delighted that Paolo has agreed to join Kesios as Executive Chairman. He brings a wealth of industry experience, which has already proved to be invaluable to PsiOxus and no doubt will help the Kesios team to accelerate the development of their programme.

“The fact that we are able to attract such experienced individuals to our portfolio, speaks volumes about the quality of the science we are commercialising and our philosophy of putting together world class management with world class science.”

Kesios, which is based in Kensington, London, was created to develop and commercialise research from the Department of Medicine at Imperial College London. 

1st June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics